JP2017519498A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519498A5
JP2017519498A5 JP2016571161A JP2016571161A JP2017519498A5 JP 2017519498 A5 JP2017519498 A5 JP 2017519498A5 JP 2016571161 A JP2016571161 A JP 2016571161A JP 2016571161 A JP2016571161 A JP 2016571161A JP 2017519498 A5 JP2017519498 A5 JP 2017519498A5
Authority
JP
Japan
Prior art keywords
ccl21
pulmonary hypertension
protein
expression
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016571161A
Other languages
English (en)
Japanese (ja)
Other versions
JP6622722B2 (ja
JP2017519498A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/054082 external-priority patent/WO2015186037A1/en
Publication of JP2017519498A publication Critical patent/JP2017519498A/ja
Publication of JP2017519498A5 publication Critical patent/JP2017519498A5/ja
Application granted granted Critical
Publication of JP6622722B2 publication Critical patent/JP6622722B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016571161A 2014-06-03 2015-05-29 肺高血圧症バイオマーカー Active JP6622722B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14170962 2014-06-03
EP14170962.6 2014-06-03
PCT/IB2015/054082 WO2015186037A1 (en) 2014-06-03 2015-05-29 Pulmonary hypertension biomarker

Publications (3)

Publication Number Publication Date
JP2017519498A JP2017519498A (ja) 2017-07-20
JP2017519498A5 true JP2017519498A5 (enExample) 2018-07-05
JP6622722B2 JP6622722B2 (ja) 2019-12-18

Family

ID=50842165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016571161A Active JP6622722B2 (ja) 2014-06-03 2015-05-29 肺高血圧症バイオマーカー

Country Status (11)

Country Link
US (3) US20170088897A1 (enExample)
EP (1) EP3152327B1 (enExample)
JP (1) JP6622722B2 (enExample)
KR (1) KR20170013261A (enExample)
CN (1) CN106460059B (enExample)
AU (1) AU2015270185B2 (enExample)
CA (1) CA2950527A1 (enExample)
EA (1) EA201692350A1 (enExample)
ES (1) ES2747381T3 (enExample)
MX (1) MX2016015930A (enExample)
WO (1) WO2015186037A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3152327B1 (en) 2014-06-03 2019-06-26 Novartis AG Pulmonary hypertension biomarker
WO2018089720A1 (en) * 2016-11-10 2018-05-17 Auburn University Method and system for evaluating blood vessel
CN106978485A (zh) * 2017-03-22 2017-07-25 首都医科大学 卵泡抑素样蛋白1对肺动脉高压的保护作用
EP3624821A4 (en) * 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION
CN107436333B (zh) * 2017-09-05 2019-12-20 中国医学科学院阜外医院 精胺作为标志物在制备肺动脉高压的诊断产品中的应用及医疗器械
JPWO2022202950A1 (enExample) * 2021-03-25 2022-09-29
CN113493829B (zh) * 2021-09-09 2021-11-12 中日友好医院(中日友好临床医学研究所) 生物标志物在肺动脉高压诊疗中的应用
CN115558711A (zh) * 2022-08-02 2023-01-03 上海市肺科医院 肺动脉高压生物标志物
CN118330204A (zh) * 2022-11-01 2024-07-12 中南大学 肺动脉高压的生物标志物及其应用
CN119193817A (zh) * 2024-11-15 2024-12-27 赣南医科大学第一附属医院 一种评估先天性心脏病相关肺动脉高压不可逆的生物标志物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US20060019272A1 (en) * 2004-05-03 2006-01-26 The Regents Of The University Of Colorado Diagnosis of disease and monitoring of therapy using gene expression analysis of peripheral blood cells
JP4657757B2 (ja) * 2005-02-23 2011-03-23 株式会社膠原病研究所 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
EP2491932A3 (en) * 2007-02-09 2012-12-12 United Therapeutics Corporation Use of biomarkers for monitoring the course of treatment of a pulmonary disease upon treatment with treprostinil
KR101362951B1 (ko) * 2007-04-26 2014-02-28 동국대학교 산학협력단 기미 형성 예지방법 및 기미 형성 예지용 진단 키트
WO2009123730A1 (en) * 2008-04-02 2009-10-08 The Trustees Of The University Of Pennsylvania Methods for diagnosis and prognosis of pulmonary hypertension
CN101318932A (zh) * 2008-07-15 2008-12-10 东华大学 2′-羧基-5′-氟联苯衍生物、其制备及应用
WO2011080050A2 (en) * 2009-12-11 2011-07-07 Novartis Ag Binding molecules
EP2694975A1 (en) * 2011-04-08 2014-02-12 Biogen Idec MA Inc. Biomarkers predictive of therapeutic responsiveness to ifnbeta and uses thereof
GB201118840D0 (en) * 2011-11-01 2011-12-14 Univ Sheffield Pulmonary hypertension II
EP3152327B1 (en) 2014-06-03 2019-06-26 Novartis AG Pulmonary hypertension biomarker

Similar Documents

Publication Publication Date Title
JP2017519498A5 (enExample)
EP3140427B1 (en) Biomarkers for response to pi3k inhibitors
US20190203295A1 (en) Methods of predicting complication and surgery in crohn's disease
CN102016072A (zh) 抗病毒疗法
JP2017513937A5 (enExample)
KR102341336B1 (ko) 만성간질환의 예후 예측용 바이오마커 조성물
JP2009541336A (ja) アルツハイマー病の進行に関するバイオマーカー
RU2016144177A (ru) Способы избирательного лечения астмы с использованием антагонистов il-13
RU2018108831A (ru) Биомаркеры для лечения очаговой алопеции
WO2011017120A1 (en) Use of ccr9, ccl25, batf and il17/il23 pathway variants to diagnose and treat inflammatory bowel disease
US20120088245A1 (en) Methods of diagnosing insulin resistance and sensitivity
WO2011116111A1 (en) Methods of using prdm1 genetic variants to prognose, diagnose and treat inflammatory bowel disease
JP2019187413A (ja) ループス腎炎の検出またはそのリスクを予測する方法およびその応用
CN107400708B (zh) Xrcc1基因多态性在风湿性关节炎诊断有效性中的用途
JP2023552199A (ja) コロナウイルス感染症を発症するリスクが高い対象を特定する方法及びその治療法
WO2010075584A1 (en) Methods of diagnosing and predicting crohns disease from childhood hygiene and serological profiles
RU2015144019A (ru) Биомаркеры фармакодинамического ответа опухоли
CN104419748B (zh) 利用基因型检测强直性脊柱炎易感性的方法和试剂盒
JP6494356B2 (ja) 非アルコール性脂肪性肝疾患及び/又は非アルコール性脂肪肝炎の発症リスク及び/又は重症化リスクの判定方法、並びに該判定用オリゴヌクレオチドキット
US20240103001A1 (en) Markers for diagnosing infections
KR20160035230A (ko) 만성폐쇄성폐질환 진단용 마커 조성물
Santonastaso et al. A simple and high sensitive method for detection of B-RAF 1799T> A (V600E) mutation in the thyroid fine needle aspirate
JP2016189746A (ja) プライマー対、プローブ、薬剤耐性c型肝炎ウイルスの検出キット、薬剤耐性c型肝炎ウイルスの検出方法およびc型肝炎の予後予測方法
ES2640524B1 (es) Uso de tcfl5/cha como nuevo marcador para el pronóstico y/o diagnóstico diferencial de leucemias linfoblásticas agudas
KR100908125B1 (ko) 심근 경색에 관련된 유전자 다형성 및 그의 용도